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Literature Review  
Epithelial ovarian cancer, the most lethal of the gynecological cancers17, is typically 
diagnosed at advanced stages19. Women diagnosed with advance-staged (i.e., stage III and IV 
according to the International Federation of Gynecology and Obstetrics) epithelial ovarian 
cancer are more likely to have recurrent episodes within 18 months17. According to a 2012-
2016 case analysis conducted by the surveillance, epidemiology, and end results, or SEER 
program, the incidence of ovarian cancer was 11.4 per 100,000 women in all races per year 
with the highest incidence in non-Hispanic whites, of 11.9 per 100,000 women and the 
lowest incidence in Asians / Pacific Islanders women, of 9.4 per 100,000 persons per year. 
The mortality incidence was 7.0 per 100,000 persons in all races per year in the United 
States43.  
Many cancers originate from genetic mutations, including ovarian cancer26. Studies 
indicate epithelial ovarian tumors develop in two distinctive pathways with type I arising 
from ovarian epithelium and inclusion germ cell layers and type II deriving from fallopian 
tubular epithelial origins. The mutation product of p53 results in various clinical symptoms 
and end points20,33. Clinicians also have recognized the association of BRCA1 and BRCA2 
genes with both of ovarian cancer and breast cancer2. A multivariate analysis conducted by 
Gallagher et al.14 revealed that multiple organ systems are prone to be involved during an 
ovarian malignancy, because there is a lack of distinct symptomatology, which allows the 
cancer to spread prior to detection.  
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Numerous studies also have indicated assorted risk factors contribute to the incidence 
and survival rate identifying racial/ethnical differences, genetic risk factors as the BRCA 
genes, and nongenetic risk factors including reproductive and hormonal factors, 
environmental and lifestyle factors. The racial differences in incidence and survival rates 
within the United States resemble the global pattern, with the highest incidence and mortality 
rates among non-Hispanic whites, followed by Hispanics, and the lowest incidence and 
mortality rates are among non-Hispanic blacks and Asians25,43. The exact causes of racial 
disparities of epithelial ovarian cancer is still left unclear, the reasons are likely to be 
diverse5,21.  
Luteinizing hormone (LH) and follicle-stimulating hormone (FSH) both stimulate the 
ovaries to produce steroids in females25. Simon et al (1983) concluded, based on in vitro 
studies, that these hormones contribute to the malignant epithelial tumors. Aside from the 
oral contraceptive use research conducted by CDC32, several hormonal factors also have been 
associated with the development of epithelial ovarian cancer. Studies have suggested an 
association between lower parity and an increased risk of developing aggressive epithelial 
ovarian cancer6,23. Women with longer ovulatory history are exposed to a greater risk of 
advanced epithelial ovarian cancer as well23. Women who have had a hysterectomy or 
experienced early-age menopause are at reduced risk of epithelial ovarian cancer3. Menstrual 
cycle irregularity and younger age at menarche also have been associated with lower risk of 




From 1990s to 2000s, there had been seven new hormonal contraceptive regimens 
approved by the Federal Drug and Administration (FDA). The birth control shot, depot 
medroxyprogesterone acetate (DMPA) along with the arm implant were introduced in the 
1990s. The intrauterine device (IUD) that releases levonorgestrel daily was approved in 
2000. The following year, transdermal patch and vaginal ring were brought to the market. In 
2003, combined oral contraceptive were introduced to the public and became common and 
popular7,39. All these various types of hormonal contraceptives differ in effectiveness and 
availability, but they all introduce hormones to regulate ovulation and inhibit body’s natural 
cyclic hormones to prevent pregnancy44. 
Decades of research suggest that there are many factors related to the prognostic 
characteristics of epithelial ovarian cancer; in fact, abundant sources have investigated the 
association of hormonal factors to epithelial ovarian cancer. Thigpen et al (1993) analyzed a 
pooled database from the Gynecologic Oncology Group and specified age as a determinant 
for pathological outcome in which women aged 69 and older had a poorer prognosis than 
younger women34. One of the early studies, conducted in the 1980s by the United States 
Centers for Disease Control and Prevention (CDC), the Cancer and Steroid Hormone Study 
(CASH), revealed that regular users of contraceptive pills for 10 years or more had a lower 
lifetime risk of epithelial ovarian cancer38. Based on such findings, a World Health 
Organization collaborative study further indicated that there were no remarkable differences 
in the level of protection based on the levels of dosage in contraceptive pills27. Furthermore, 
a meta-analysis conducted by Wheeler et al (2019) identified that any type of intrauterine 
device they investigated was associated with a lower incidence of ovarian cancer36. 
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Public Health Significance 
Ovarian cancer is the fifth leading cause of death from cancer among adult females 
and the second most common gynecologic cancer in the United States42. Ovarian cancer 
usually goes undetected until it has already developed into an advanced stage and has spread 
to the pelvis and abdomen. The survival rate for ovarian cancer is generally as high as 92% 
when detected in the early stage, however, due to the non-specific symptoms of ovarian 
cancer and the lack of early detection tests, the 5-year survival rate for advanced stages can 
be low as 30% in the United States40. Moreover, about 75% of patients are diagnosed at 
advanced stages because of the asymptomatic nature of EOC19. EOC is the most predominant 
pathological subtype accounting for more than 90% of all ovarian cancer33. According to the 
global statistics report published by the World Ovarian Cancer Coalition in 2018, the risk of 
ovarian cancer increases in more developed countries and urbanized areas, though the 
survival rates in higher income countries vary by stage of diagnosis, awareness of the 
disease, attitude and accessibility towards treatment41. 
As noted, the development of EOC is associated with hormone-related risk factors, 
disparity in the EOC development may be induced by various hormonal contraceptives13. 
This study was designed to enhance our understanding of the hormonal factors associated 
with the development of EOC by examining across various contraceptive methods. 
Identifying unique and shared risk factors that contribute to increased risk for EOC will allow 





As stated above, multiple studies, including population-based studies have been 
conducted that reveal an association between use of hormonal contraceptives and the 
development of EOC. All studies considered for this review were screened using 
predetermined inclusion and exclusion criteria. This systematic review analyzed all eligible 
studies, examined the study measures used, and evaluated the validity and reliability of each 
source. 
 
Research Objectives  
The overall goal of this study is to systematically analyze peer reviewed publications, 
published between 2009 and 2019, that examined associations between hormonal risk factors 
related to various types of contraceptive use and the subsequent development of epithelial 
ovarian cancer.  
 
Specific Aim  
To identify potential hormonal risk factors induced by various hormonal 
contraceptive use that influence the development of advanced stage II, III and stage IV 






To meet the study objective and aim, I completed a systematic literature review. All 
articles have been identified through a key word search (see Key Word Search next). The 
purpose of this study is to methodically identify publications between 2009 and 2019, which 
include analytical studies that examined advanced stage II, III and stage IV epithelial ovarian 
cancer and use of hormonal contraceptives. The 10-year span for publications was set 
considering the innovative emergence of hormonal contraceptive methods38. This systematic 
review will analyze the differences in the development of ovarian cancer across various types 
of hormonal contraceptive. Acquired data were secondary, sources were identified from 
online academic databases, including using pre-determined inclusion and exclusion criteria.  
All selected articles have been reviewed systematically. Articles that employed 
nonrandomized samples and meta-analyses were analyzed using the Newcastle-Ottawa Scale 
(NOS). The NOS has two assessment scales that have been designated for case-control 
studies and cohort studies. The cross-sectional studies for this review were analyzed based on 
the case-control studies considering the analytical parameters. The instruments used the 
intraclass correlation coefficient (ICC)- and normative score to evaluate the extracted data for 
internal reliability through Spearman rho to calculate the between-scale correlation10.  
 
Key Word Search 
Epithelial ovarian cancer, hormonal contraceptive, contraceptive skin patch, birth control 
pill, vaginal ring, hormone-releasing contraceptive coils, hormone injection, hormonal birth 




1. Subjects: published peer-reviewed articles 
2. Time: January 1, 2009 to December 31, 2019 
3. Study design: systematic review  
 
Eligibility Criteria   
1. Inclusion 
a. Study design: randomized controlled trials, cohort studies, case-control 
studies, cross-sectional studies, and statistical analyses. 
b. Research type: quantitative research 
c. Study outcome measures: incidence rate, incidence rate ratio, percentage 
attributable risk, hazards ratio, odds ratio, mortality risk 
d. Risk factors: hormonal contraceptive methods including birth control pills, 
contraceptive skin patch, vaginal ring, hormone-releasing contraceptive coils, 
intrauterine device, arm implant, tubal ligation, and birth control injection.  
2. Exclusion  
a. Sources: non-English sources 
b. Research type: qualitative research 
 
Data Collection 
Each database has been reviewed for journal titles, abstracts, and full-text articles to 
avoid compromising sensitivity. All reference lists from the selected journal articles were 
analyzed for potential inclusion of studies missed by the initial search. The selected studies 
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were screened for potential duplications of study populations in the Method section. In this 
case, the study with higher level of evidence, greater number of patients, longer follow-up 
period, or more thorough reporting of primary outcomes of interest would be used15. All the 
eligible peer-reviewed publications were recorded in an accrual log to extract the valid 
information suitable for the study objectives (See Accrual Log for Literature Review below).  
 
 
Accrual Log for Literature Review 














        
        
        
        
        
        
        
        
        




Human Subjects Considerations 
Due to the characteristic of systematic-review analysis, the human subject’s safety 
considerations will not be applied to this study.   
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RESULTS 
A total of 24 records were identified from the primary searches; ten full reports were 
included in this review after full-text assessment3,8,9,11,13,16,18,31,35,37. Seven of the ten 
comprised studies that investigated the association between oral 
contraceptive3,8,9,11,13,18,31,35,37,, the most common form of hormonal contraceptive39, and the 
development of epithelial ovarian cancer (Appendix A). The three other reports examined 
tubal ligation31, depot medroxyprogesterone acetate (DMPA)37 and IUD16, and were grouped 
for assessment in Appendix B.  
Out of the seven studies investigating the association between oral contraceptive use 
and the development of epithelial ovarian cancer (Appendix A), three yielded odds ratio, two 
yielded hazards ratio, one relative ratio, and one investigated mortality risk and overall 
survival time as measures of risk. For the studies that examined hormonal contraceptives 
other than OC (Appendix B), two studies yielded odds ratio and one used hazards ratio as 
measures of risk.  
 
Quality Assessment  
The ten selected studies had been divided into two groups based on the NOS scale for 
the study characteristics – cohort studies and case-control studies. The quality assessment for 
cohort studies have been recorded in Appendix C, and Appendix D concludes the quality 
assessment for case-control studies and the derivatives.  
As can be seen in Appendices C and D, the selected cohort studies in Appendix C are 
of higher quality based on NOS assessment scale than the selected cross-sectional studies in 
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Appendix D. Only one out of the five selected cohort studies, published by Fortner et al 
(2015), did quality for full-credit because it did not conclude statement regarding adequacy 
of follow-up11. Three of the five selected cross-sectional studies (Appendix D) defined the 
exposure using written self-reports8,11,31, which can potentially lead to information bias1. 
Furthermore, three out of the five cross-sectional studies did not report or discuss the 
non-response rate8,31,37; non-response bias can also impact the reliability for the included 
studies29.  
 
Study Characteristics  
Seven out of the ten studies investigating the association between oral contraceptives 
and advance-stage ovarian cancer are summarized in Appendix A. Appendix B summarizes 
the other three forms of hormonal contraceptives. Five of the ten studies were cohort studies 
(Appendix C), five were case-control studies or derivatives of case-control studies (Appendix 
D). Three out of the seven studies examining the association between oral contraceptive use 
and epithelial ovarian cancer analyzed odds ratio as the outcome measure8,9,11; two analyzed 
hazards ratio as the outcome measure3,35; one measured mortality risks18; and one measured 
relative risk12.  
Five out of the seven studies reported in Appendix A concluded a protective effect 
between oral contraceptive use and the development of ovarian cancer - three reported an 
association between OC use and lowered risk in ovarian cancer development9,11,35; two 
reported an association between OC use and improved cervical cancer survival outcomes13,18. 
In contrast, two other studies included in Appendix A. Chen et al (2016) described an 
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association between OC users and higher frequency of ovarian cancer compared to non-OC 
users8 and Besevic et al, (2015) reported an association between longer duration of OC use 
and worse ovarian cancer survival3.  
The studies investigating the association between other methods of hormonal 
contraceptives and advance-stage ovarian cancer have been summarized in Appendix B. One 
study, which investigated depot medroxyprogesterone acetate (DMPA), the birth control 
shot37, reported a protective association between DMPA and EOC. Huang et al (2014) 
examined intrauterine devices (IUDs) and tubal ligation; their study results revealed a 
nonsignificant association between IUD use and ovarian cancer risk16 in contrast tubal 
ligation was association with reduced ovarian cancer risk31. Two of the three studies were 
based on case-control studies31,37 and the third study was cohort study16. Two out of the three 
studies investigating other forms of contraceptives measured odds ratio, the other use 




Seven out of the ten articles summarized in the current report described a significant 
reduction in risk of aggressive epithelial ovarian cancer development with the use of 
hormonal contraceptives in the form of oral contraceptives, tubal ligation, Depot 
medroxyprogesterone acetate (DMPA), Intrauterine Device (IUD). Specifically, a protective 
association of ever use and longer duration of hormonal contraceptive and the development 
of EOC was reported among these seven studies that concluded reduced risk. Two studies 
reported a nonsignificant result, but the direction of these associations suggested a protective 
association between contraceptive use and development of aggressive epithelial ovarian 
cancer9,16. The study conducted by Besevic et al (2015), is the only study that reported a 
harmful effect3.  
Based on the European Prospective Investigation into Cancer initiative (EPIC), they 
conclude that longer durations of OC use was associated with shorter survival time for 
advanced-stage EOC patients (>10 years vs ⩽1 year of use: HR=1.74 95% CI=1.10–
2.75, Ptrend=0.01) 3. However, Tsilidis et al.35 and Fortner et al 13 also measured the 
association between oral contraceptive use and the risk of ovarian cancer using the EPIC 
data; both obtained conflicting results. Tsilidis et al concluded that women who used oral 
contraceptive for 10 or more years had a significant 45% (HR, 0.55; 95% CI, 0.41–0.75) 
lower risk compared with users of 1 year or less (P-trend, <0.01)35. Fortner et al obtained a  
significant association between long duration of OC use and the risk of advanced-stage 
EOC13. The discrepancy between the Besevic study and the latter two studies was the 
identification of confounders in the process of statistical adjustment. Besevic et al controlled 
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for age, BMI, tumor stage, and smoking history; Tsilidis et al controlled for age, BMI, 
menopausal status and parity; Fortner et al controlled for age, menopausal status, parity, and 
menstrual cycle irregularity. The discrepancy of covariates may introduce a confounding bias 
into the association, therefore, Besevic concluded an inverse association when all three 
studies were derived from the same dataset.  
All of selected studies suggested for a protective association between hormonal 
contraceptives and the development of EOC controlled for, menopausal status, parity, and 
age8,9,11,13,16,18,31,35,37, which have all been reported as potential confounders for birth control 
use and epithelial ovarian cancer13. According to CDC (2019), women with higher 
socioeconomic status tend to have better survival and less incidence due to access to 
healthcare42. Furthermore, previous research has demonstrated that age, lower parity and 
post-menopausal status has been associated with higher risk epithelial ovarian cancer28.  
Out of the ten reported articles, four types of hormonal contraceptives were included, 
many other common forms of birth control such as birth control implant and birth control 
patch, have yet to be investigated with the association of EOC. Excluding OC, this study 
identified only one article investigating the association between each form of hormonal 
contraceptives and EOC. 
 
Strengths and Limitations 
As with most research, there are strengths and limitations of this review. One of the 
strengths of this systematic review is the well-defined eligibility criteria for data acquisition. 
The inclusion criteria for the publication year between 2009 and 2019 refined the relevancy
16 
 of the contraceptive methods that were assessed in the selected articles. Many of the 
published articles were based on large dataset from cancer registries and analyzed validated 
cases, which thereby eliminates information bias. Most of the reported studies did not 
disclose their follow-up rates, which can potentially induce selection bias into the studies. 
Four of the ten studies were conducted in Europe, and all analyzed OC use as the birth 
control method based on the EPIC study. Three studies were conducted in Asia and the 
remaining three were American studies based on data from cancer registries. This diversity of 
racial/ethnic groups can also bias the results in a comprehensive comparison such as this. The 
genomic variation between these racial/ethnical groups could also serve as a confounding 
factor in these studies and bias the measure of association.  
The investigated study samples ranged from hundreds to hundreds of thousands, these 
large datasets can significantly impact the representative of the selected populations. 
However, all the selected articles did not analyze the measure of association with the 
considerations of potential confounders that would be contributed to the hormone levels of 
patients, such as the discrepant oral contraceptive forms combined estrogen-progesterone, 
progesterone only and the continuous or extended use pill12. As a final limitation for this 
review, the selected articles analyzed three forms of hormonal contraceptive methods; thus, 
the association between other hormonal contraceptives, the skin patch and vaginal ring for 




  Various hormonal contraceptives were analyzed for their association with the 
development of ovarian cancer, and most revealed a protective effect among women. Future 
studies should analyze the association based on the stratification of race/ethnics, genomic 
variations, the specific form of oral contraceptive pills, and other topical hormonal 
contraceptive methods.   
 
Appendix A – Literature review of other forms of hormonal contraceptives 
APPENDIX A  
 
 




Study Setting & Study Population Study Intervention Key Findings
Quality 
Assessment
Kolomeyevskaya, N. V. et al. 
(2015). Oral Contraceptive Use 
and Reproductive Characteristics 
Affect Survival in Patients with 
Epithelial Ovarian Cancer: A 
Cohort Study. International 
Journal of Gynecological Cancer. 










Women aged 18 to 99 years with 
newly diagnosed EOC, fallopian 
tube, or primary peritoneal 
carcinoma seeking care at 
Rosewell Park Cancer Institute. 
Overall survival time was calculated in months from the date of 
diagnosis until the date of death or of last follow-up. Patients alive 
at last contact were censored at the date of last contact. The 
Kaplan-Meier technique was used to compare survival across 
various exposures. Categorical exposures were tested using the log-
rank test, whereas continuous variables were analyzed with Cox 
regression. A threshold of P  < 0.20 was used to identify candidate 
variables for final models. Final models were selected using a 
forward selection process; for consistency, covariates identified for 
any model were included in all adjusted models. Cox regression 
was used to compute crude hazards ratios (HRs) and adjusted HRs 
(aHRs), as well as 95% confidence intervals (95% CIs). Linearity of 
associations between continuous variables and survival were 
confirmed using linear spline models. The proportional hazards 
assumption was verified for each factor of interest.
A history of OC use and parity are 
associated with improved survival in 
patients diagnosed with ovarian cancer. 
History of OC use was associated with a 35-
month improvement in median overall 
survival (81 vs 46 months; HR, 0.51; 95% CI, 
0.39–0.66), although this association was 
attenuated when analyses were adjusted 
for age at diagnosis, stage, and histologic 
subtype (aHR, 0.71; 95% CI, 0.53–0.97).
9/9
Cook, L. S. and Pestak, C. R. et 
al. (2017). Combined Oral 
Contraceptives Use Before the 
First Birth and Epithelial Ovarian 
Cancer Risk. Birtish Journal of 







Briefly, cases were identified from 
the population-based BC and AB 
cancer registries who were: age 
20–79 years (40–79 in AB); 
diagnosed with first primary, 
incident, histologically confirmed 
EOC (invasive EOC in AB); and able 
to complete study in English. A 
total of 1505 cases (60% of 2522 
eligible) completed the study. 
Eligible controls identified from 
provincial health rosters and a 
mammography screening program 
(Eheman et al, 2014) were: aged 
20–79 years (40–79 in AB); able to 
complete study in English; and, had 
at least one ovary. A total of 2564 
(53% of 4838 eligible) completed 
the study.
Logistic regression to estimate adjusted odds ratios (aORs) and 
95% confidence intervals (CIs) in R software. Final aORs included 
matching variables , age at FTTP, first degree family female breast 
or ovarian cancer, tubal ligation, and BMI. Histotype-specific 
analyses were restricted to high-grade serous and combined 
endometrioid/clear cell. 
Any COC use was associated with a 
reduction in risk (aOR=0.58, 95% CI=0.49, 
0.69). Among COC users, risk was most 
strongly reduced with longer durations of 
use overall, within more recent time since 
last use, and for younger ages at first use.
7/9
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Study Setting & Study Population Study Intervention Key Findings
Quality 
Assessment
Tsilidis, K. K. and Allen N. E et 
al. (2011). Oral Contraceptive 
Use and Reproductive Factors 
and risk of ovarian cancer in the 
European Perspective 
Inesvtigation into Cancer and 
Nutrition. British Journal of 
Cancer. 105 (9): 1436-42. DOI: 
10.1038/bjc.2011.371. 
PubMed Central Cohort Study Hazards ratio
Participants recruited between 
1992 and 2000 in 23 centers in 10 
European countries (Denmark, 
France, Germany, Greece, Italy, 
The Netherlands, Norway, Spain, 
Sweden and the United Kingdom) 
for the European Prospective 
Investigation into Cancer and 
Nutrition (EPIC). Incident cancer 
cases were identified through 
linkage to population cancer 
registries in Denmark, Italy, The 
Netherlands, Norway, Spain, 
Sweden and the UK, or using a 
combination of methods.
Hazard ratios (HRs) and 95% confidence intervals (CIs) were 
estimated using Cox proportional hazard models stratified by 
centre and age, and adjusted for smoking status, body mass index, 
unilateral ovariectomy, simple hysterectomy, menopausal 
hormone therapy, and mutually adjusted for age at menarche, age 
at menopause, number of full-term pregnancies and duration of 
oral contraceptive use. including linkage to health insurance 
records, cancer and pathology registries, and active follow-up of 
study participants or their next of kin in France, Germany and 
Greece.
Women who used oral contraceptives for 
10 or more years had a significant 45% (HR, 
0.55; 95% CI, 0.41–0.75) lower risk 
compared with users of 1 year or less (P -
trend, <0.01). Compared with nulliparous 
women, parous women had a 29% (HR, 
0.71; 95% CI, 0.59–0.87) lower risk, with an 
8% reduction in risk for each additional 
pregnancy. A high age at menopause was 
associated with a higher risk of ovarian 
cancer (>52 vs  ⩽45 years: HR, 1.46; 95% CI, 
1.06–1.99; P -trend, 0.02). Age at menarche, 
age at first full-term pregnancy, incomplete 
pregnancies and breastfeeding were not 
associated with risk.
9/9
Fortner, R. T. and Ose, J. et al. 
(2015). Reproductive and 
hormone-related risk factors for 
epithelial ovarian cancer by 
histologic pathways, 
invasiveness and histologic 
subtypes: Results from the EPIC 
cohort. International Journal of 




Cohort study Relative risks 
The EPIC cohort was established 
between 1992 and 2000 at 23 
centers in 10 countries: Denmark, 
France, Germany, Greece, Italy, the 
Netherlands, Norway, Spain, 
Sweden and the United Kingdom. 
Participants were excluded if they 
reported history of prior cancer at 
recruitment (except non-
melanoma skin cancer), had 
incomplete baseline data, reported 
bilateral oophorectomy at baseline, 
or women missing data on all 
investigated reproductive and 
hormone-related risk factors, 
leaving a study population of 
334,126 women.
Main exposure variables were categorized as follows: age at 
menarche:  13, 14,  15 years; age at menopause:  48, 49–50, 
51–54,  55 years; full-term pregnancy: yes/no; number of full-
term. All analyses were adjusted for OC use (ever/never), HRT use 
(ever/never), age at menopause (continuous; pre-/perimenopausal 
assigned median age at menopause), menopausal status at 
baseline (pre- or perimenopausal/postmenopausal), and full-term 
pregnancy (ever/never), except when the variable was the main 
effect. pregnancies: 0, 1, 2, 31; breastfed: yes/ no; menstrual cycle 
regularity:  26 days, 27–29 days, 301 days, none or irregular; OC 
use: yes/no; OC duration: never user,  1 year, 1–4 years, 5–9 years, 
 10 years; hysterectomy: yes/no; HRT use: yes/no; BMI: normal 
weight (<25 kg m22), overweight (25–30 kg m22), obese ( 30 mg 
m22).
Duration of OC use and number of full-term 
pregnancies were inversely associated with 
both type I and type II, but not borderline, 
tumors (e.g.,  10 years vs. never use of OC: 
borderline, RR: 0.75. duration of OC use 
was only significantly associated with 
reduced risk of serous tumors (e.g., OC use 
 10 years vs. never user, RR: 0.61 
[0.46–0.82], ptrend < 0.01, phet 5 0.86) 
[0.35– 1.61], ptrend 5 0.22; type I, RR: 0.54 
[0.31–0.94], ptrend 5 0.01; type II, RR: 0.71 
[0.51–0.97], ptrend 5 0.01; phet 5 0.22).. 
Established protective factors, including 
duration of oral contraceptive use and full 
term pregnancy, were consistently inversely 
associated with risk across histologic 
subtypes (e.g., ever full-term pregnancy: 
serous, RR: 0.73 [0.58–0.92]; mucinous, RR: 
0.53 [0.30–0.95]; endometrioid, RR: 0.65 
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Study Setting & Study Population Study Intervention Key Findings Quality Assessment
Chen, Y., Tan, X., Ding, Y., Mai, 
B., Huang, X., Hu, G., & Luo, X. 
(2016). WWOX CNV-67048 
Functions as a Risk Factor for 
Epithelial Ovarian Cancer in 
Chinese Women by Negatively 
Interacting with Oral 
Contraceptive Use. BioMed 
research international , 2016 , 
6594039. 
doi:10.1155/2016/6594039
PubMed Central case-control study odds ratio
549 EOC patients and 571 age (±5 
years) matched cancer-free 
controls were recruited from the 
Guangdong Provincial Maternity 
and Child Care Center in 
Guangzhou, China. Individuals with 
tumor history were excluded. Each 
participant was asked to denote 
3 mL peripheral blood sample and 
complete a questionnaire to collect 
their data on sociodemographic, 
smoking status, alcohol 
consumption, menstrual and 
reproductive histories, and 
contraceptive use.
The chi-square test was used to assess differences in the 
distributions of CNV-67048 copy number between EOC cases and 
controls. The unconditional logistic regression model with or 
without adjustment for surrounding factors including age, age at 
menarche, number of births, menstrual history, oral contraceptive 
use, family history of cancer, smoking status, and alcohol intake 
was used to infer odds ratio (OR) and 95% confidence interval 
(95% CI) for each association between the CNV-67048 and EOC 
risk. 
significantly higher frequency of menarche 
age less than 15 years, births number no 
less than 4, and reported null oral 
contraceptive use were observed in EOC 
cases than in controls (P  values are 0.039, 
<0.001, and 0.039 in turn). 
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SpringerLink Nested case-control odds ratio
The participants were recruited 
from the NYU Women’s Health 
Study (NYUWHS), the Northern 
Sweden Health and Disease Study 
(NSHDS), and the ORDET cohort in 
Italy. In total, 230 ovarian cancer 
cases and 432 controls (~2 per case 
matched on age, menopausal 
status, and date of blood sampling) 
were included.
Cross-sectional analyses were preformed mutually adjusted for all 
factors significantly associated with prolactin levels in our study 
(age, parity, oral contraceptive use, and menopausal status). 
Multivariate conditional logistic regression models were adjusted 
for parity (ever/never had a full-term pregnancy) and use of oral 
contraceptives (OCs, past/never).
Cases were less likely ot have used OCs (64 
vs. 70 %, p = 0.26). Past use of OCs was 
associated with lower prolactin levels in 
both pre- and post-menopausal women.
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hazards ratio 
from death 
of EOC and 
EOC-related 
cause
Cases were identified through 
linkage with national cancer 
registries in Denmark, Italy, The 
Netherlands, Norway, Spain, 
Sweden and the UK. In France, 
Germany and Greece, cases were 
identified using insurance records, 
cancer registries and active follow-
up of participants. Data on tumour 
invasiveness, histology, stage and 
grade were available from cancer 
registries and a pathology record 
review. A total of 1025 women 
diagnosed with EOC. 
Hazard ratios (HRs) and 95% confidence intervals (CIs) were 
calculated using Cox proportional hazards regression models. 
Person-time was calculated as the number of days between EOC 
diagnosis and the date of death, emigration, loss to follow-up or 
censoring, whichever occurred first. Multivariable models were 
adjusted for covariates that were selected a priori  because of their 
known influence on risk of EOC death; age at diagnosis 
(continuous), BMI (<23 kg m−2, ⩾23–<25 (reference), ⩾25–<30, 
⩾30), tumour stage (local (reference), regional, metastatic, 
unknown) and smoking status (never (reference), former, current, 
unknown). 
Among OC users a longer duration of use 
was associated with a worse survival (>10 
years vs  ⩽1 year of use: HR=1.74 95% 
CI=1.10–2.75, Ptrend=0.01). In a uniform 
subgroup of FIGO stage II/III cases (all 
histological subtypes), there was no 
association between OC use or OC duration 
of use with EOC-specific survival. 
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ligation and risk of ovarian cancer subtypes: a 
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Odds ratio and 95% 
confidence interval
Primary data from 13 population-based 
case-control studies,  Cases were women 
newly diagnosed with invasive epithelial 
ovarian cancer (N = 7942) or borderline 
tumours (N = 2215). Eligible control 
women had at least one intact ovary and 
no history of ovarian cancer (N = 13 904).
Controls were matched to cases on geographical 
region and age in all sites, and when warranted on 
race/ethnicity. Odds ratios (ORs) and 95% confidence 
intervals (CIs) were estimated using conditional 
logistic regression matched on sets determined by 
combinations of site, race/ethnicity  (non-Hispanic 
White, Hispanic White, Black, Asian, other) and 5-year 
age categories, and adjusted for age as a continuous 
variable, oral contraception use and number of full-
term pregnancies.
Tubal ligation was associated with a 29% 
reduced risk of invasive ovarian cancer 
overall (OR, 0.71; 95% CI, 0.66-0.77; P < 
0.001), after accounting for study site, age, 
race/ethnicity, oral contraceptive use and 
number of full-term births. 
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The odds ratio (OR) and 95% 
confidence interval (95% CI) 
were calculated to assess the 
relationship between DMPA 
and EOC.
From 12 hospitals located across 
Thailand, three hundred and thirty 
patients with EOC (‘cases’) and 982 
matched controls were recruited from 
the 12 hospitals. Cases were newly 
diagnosed patients with EOC, 
demonstrated pathologically. Controls 
were age-matched patients admitted to 
different wards in the same hospital. 
Cases and controls were interviewed by trained 
interviewers using a standardised pre-tested 
questionnaire. The factors associated with EOC were 
evaluated using univariate and multivariate analyses.
The use of DMPA was found to be associated 
with a 39% reduction in the risk of EOC with 
an OR of 0.61 and a 95% CI of 0.44–0.85 (P = 
0.002). A significant risk reduction (83%) was 
observed when the duration of DMPA use 
was >3 years (OR 0.17; 95% CI 0.07–0.39; P 
< 0.001). Other factors associated with a 
reduced risk of EOC were the use of 
combined oral contraceptive pills and 
breastfeeding. A factor associated with an 
increased risk of EOC was a family history of 
gynaecological cancer.
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at baseline from March 1997 to May 
2000, adult Chinese women aged 40–70 
years were recruited from seven urban 
communities of Shanghai, China. . 
Incident cancer cases were verified by 
home visits and medical chart review. 
Women who had a previous diagnosis of 
any cancer, an unverified diagnosis of 
cancer, a prior oophorectomy, unknown 
menopausal status, those who died of 
cancer without a specific cancer 
diagnosis or were lost to follow-up were 
excluded; a total of 70,259 women were 
included in our analysis.
Cox proportional hazards regression was used to 
derive hazard ratios (HRs) and 95% confidence 
intervals (CIs) for associations between ovarian 
cancer risk and contraceptive methods. Contraceptive 
methods evaluated in this study included IUD, OC, TL 
and contraceptive shots; ever use was compared with 
never use. Durations of exposure time were 
calculated as the interval between start and end of 
use, except for TL and IUD, where removal had not 
occurred by baseline interview. All analyses were 
performed using SAS version 9.3 (SAS Institute, Cary, 
NC), and a two-sided probability with a significance 
level of 0.05 was used.
Ever use of any contraception was associated 
with a nonsignificant reduction in ovarian 
cancer risk (HR: 0.86, 95% CI: 0.60–1.24). 
Longer duration of IUD use was associated 
with lower ovarian cancer risk (p-value for 
trend 5 0.04). Compared with never users, 
women with durations of IUD use longer than 
the median (20 years) were 38% less likely to 
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interest was not 
present t the 
start of study




Was follow-up long enough 
for outcomes to occur
Adequacy of follow up of 
cohorts
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represnetative of the 
average ovarian cancer 
cases in the community
drawn from the same 
community as the 
exposed cohort
written self report Yes
Study cotrols for presence or absence of 
specific medical comorbidities, as well 
as reproductive factors including the use 
of hormonal medications. Individual 
subject information on treatment and 
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9/9
Fortner, R. T. and Ose, J. et al. 
(2015). Reproductive and 
hormone-related risk factors for 
epithelial ovarian cancer by 
histologic pathways, 
invasiveness and histologic 
subtypes: Results from the EPIC 
cohort. International Journal of 
Cancer. 137: 1196 - 1208. DOI: 
10.1002/ijc.29471.
Somewhat 
represnetative of the 
average ovarian cancer 
cases in the community
Drawn from the same 
community as the 
exposed cohort
Written self report Yes
Study controls for age at menarche, age 
at menopause, parity and number of 
full-term pregnancies, breast feeding, 
menstrual cycle regularity, OC use and 
duration, menopausal hormone 




Yes No statement 8/9
Bešević, J., Gunter, M. J., 
Fortner, R. T., Tsilidis, K. K., 
Weiderpass, E., Onland-Moret, 
N. C., … Merritt, M. A. (2015). 
Reproductive factors and 
epithelial ovarian cancer 
survival in the EPIC cohort 
study. British journal of 
cancer , 113 (11), 1622–1631. 
doi:10.1038/bjc.2015.377
Somewhat 
represnetative of the 
average ovarian cancer 
cases in the community
Drawn from the same 
community as the 
exposed cohort
Written self report Yes





Subjects lost to follow up 



















that outcome of 
interest was not 
present t the 
start of study




Was follow-up long enough 
for outcomes to occur
Adequacy of follow up of 
cohorts
Huang, Z. and Gao, Y et al. 
(2014). Contraceptive methods 
and ovarian cancer risk among 
Chinese women: A report from 
the Shanghai Women's Health 
Study. International Journal of 
Cancer. 137 (3): 607-14. DOI: 
10.1002/ijc.29412. 
Somewhat 
represnetative of the 
average ovarian cancer 
cases in the community
Drawn from the same 
community as the 
exposed cohort
Structured interviews Yes
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Appendix D – Quality assessment of cross-sectional studies and derivatives 
APPENDIX D 
Comparability
Is the case definition 
adequate?





Comparability of cases and 




Same method of ascrtainment for cases 
and controls
Non-response rate
Cook, L. S. and Pestak, C. R. et al. 
(2017). Combined Oral Contraceptives 
Use Before the First Birth and 
Epithelial Ovarian Cancer Risk. British 
Journal of Cancer. 116: 265-269.  DOI: 
10.1038/bjc.2016.400. 
Yes, with independent 
validation
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Study controls for outcome 
diagnosis date and reference 
data as well as demographic, 
lifestyle, and 
medical/reproductive factors, 
women provided information on 
COC use, including dates or ages 
of use
Written self report Yes
Rate different and no 
designation (60% for 
cases and 53% for 
controls)
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